KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Purchases $134,261.64 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par acquired 14,562 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was acquired at an average price of $9.22 per share, for a total transaction of $134,261.64. Following the transaction, the insider now directly owns 5,012,796 shares of the company’s stock, valued at $46,217,979.12. This represents a 0.29 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Thursday, January 30th, Venrock Healthcare Capital Par bought 43,707 shares of KalVista Pharmaceuticals stock. The stock was acquired at an average price of $8.76 per share, for a total transaction of $382,873.32.

KalVista Pharmaceuticals Stock Performance

KALV stock opened at $9.90 on Thursday. The firm has a market cap of $489.26 million, a P/E ratio of -2.72 and a beta of 0.85. The firm’s fifty day moving average is $8.80 and its 200 day moving average is $10.77. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.30 and a 52 week high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.01. As a group, analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

Analyst Ratings Changes

KALV has been the subject of several recent analyst reports. Bank of America began coverage on KalVista Pharmaceuticals in a report on Wednesday, December 18th. They set a “buy” rating and a $22.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. Finally, Citizens Jmp raised KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $23.80.

Institutional Trading of KalVista Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. grew its holdings in shares of KalVista Pharmaceuticals by 24.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock worth $87,000 after purchasing an additional 2,043 shares during the last quarter. SG Americas Securities LLC grew its holdings in KalVista Pharmaceuticals by 10.0% in the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after acquiring an additional 1,319 shares during the last quarter. Hennion & Walsh Asset Management Inc. purchased a new position in shares of KalVista Pharmaceuticals in the fourth quarter valued at about $634,000. JPMorgan Chase & Co. raised its stake in shares of KalVista Pharmaceuticals by 8.0% during the third quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock valued at $262,000 after acquiring an additional 1,670 shares during the last quarter. Finally, Barclays PLC boosted its holdings in shares of KalVista Pharmaceuticals by 418.5% during the third quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock worth $778,000 after purchasing an additional 54,257 shares during the period.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).